Results 61 to 70 of about 1,883,437 (383)

SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment.

Annual Review of Medicine, 2021
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Dapeng Li, G. Sempowski, K. Saunders, P. Acharya, B. Haynes   +4 more
semanticscholar   +1 more source

Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts

Translational Oncology, 2017
Chemokines are small soluble molecules that play critical roles in wound healing, infection, and cancer progression. In particular, overexpression of the C-C motif chemokine ligand 2 (CCL2) in multiple cancer types correlates with poor patient prognosis.
Min Yao, Curtis Smart, Qingting Hu, Nikki Cheng   +3 more
doaj   +1 more source

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]

, 2019
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan, Carrero, Ana, Crespo, Manuel, González García, Juan, Guardional, Josep M., Gómez, Julián, Jiménez Sousa, María Angeles, Martínez, Isidoro, Resino, Salvador, Santos, Ignacio de los, The GESIDA 3603b Cohort Study Group, Vigón, Lorena, Von Wichmann, Miguel A., Vázquez Morón, Sonia, Yélamos, María Belén   +14 more
core   +4 more sources

BNT162b2 Vaccination after SARS-CoV-2 Infection Changes the Dynamics of Total and Neutralizing Antibodies against SARS-CoV-2: A 6-Month Prospective Cohort Study

Vaccines, 2023
This study aimed to analyze the dynamics, duration, and production of total and neutralizing antibodies induced by the BNT162b2 vaccine and the possible effect of gender and prior SARS-CoV-2 infection on the generation of these antibodies.
Jorge Hernández-Bello, José Julio Sierra-García-de-Quevedo, José Javier Morales-Núñez, Guillermo Santoscoy-Ascencio, Saúl Alberto Díaz-Pérez, Jesús Alberto Gutiérrez-Brito, José Francisco Muñoz-Valle   +6 more
doaj   +1 more source

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination [PDF]

, 2012
Background: One of the great challenges for an HIV vaccine is to elicit broadly neutralizing antibodies specific for conserved epitopes from which the virus cannot easily escape.
Hanson, M., Irvine, Darrell J., Kriegsman, Barry A., Mata-Fink, Jordi, Wittrup, Karl Dane   +4 more
core   +1 more source

Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis.

Clinical Infectious Diseases, 2021
Recently emerged SARS-CoV-2 variants may pose a threat to immunity. A systematic landscape of neutralizing antibodies against emerging variants is needed.
Xinhua Chen, Zhiyuan Chen, A. Azman, R. Sun, Wanying Lu, N. Zheng, Jiaxin Zhou, Qianhui Wu, X. Deng, Zeyao Zhao, Xinghui Chen, S. Ge, Juan Yang, D. Leung, Hongjie Yu   +14 more
semanticscholar   +1 more source

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. [PDF]

PLoS Pathogens, 2013
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine.
Constantinos Kurt Wibmer, Jinal N Bhiman, Elin S Gray, Nancy Tumba, Salim S Abdool Karim, Carolyn Williamson, Lynn Morris, Penny L Moore   +7 more
doaj   +1 more source

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group [PDF]

, 2010
The Global HIV Vaccine Enterprise convened a meeting of a Working Group in July 2009 to discuss recent progress in rational design of the components of an HIV vaccine, such as inserts, vectors and adjuvants,and in understanding antigen processing and ...
John Mascola, Ralph Steinman, Richter C. King, the Working Group convened by the Global HIV Vaccine Enterprise   +3 more
core   +3 more sources

Defining criteria for broadly neutralizing HIV antibodies

Frontiers in Immunology
Over the course of a few years, a small percentage of individuals with HIV-1 develop broadly neutralizing antibodies (bnAbs) capable of neutralizing diverse viruses.
Elizabeth-Sharon David-Fung, Katherine A. Belobrajdic, Jennifer P. Macke, Corey R. Quackenbush, Kumkum Ganguly, Jennifer L. Mamrosh   +5 more
doaj   +1 more source

SnapShot: Broadly Neutralizing Antibodies

Cell, 2013
Durably elicited by live attenuated virus, less durably by inactivated virusConserved bnAb epitopes:1) Ep1 (res. 380–400) 2) Ep2 (res. 190–200)3) Ep3 (res. 571–579)Despite the extensive variability of measles virus, nAb responses to vaccination are broad becausethe conserved epitopes are immunoprominent.May relate to overlap of the receptor-binding ...
Sok, Devin, Moldt, Brian, Burton, Dennis R.   +2 more
openaire   +2 more sources